McKesson Corp (NYSE: MCK) reported first-quarter FY22 adjusted EPS of $5.56, almost doubled from $2.77 a year ago, and easily beating the analyst consensus of $4.17.
Revenues increased 13% Y/Y to $62.67 billion, surpassing the consensus of $59.9 billion, driven by higher volumes from retail national account customers and market growth, partially offset by branded to generic conversions.
U.S. Pharmaceutical Segment revenues …

Full story available on Benzinga.com